Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme

Andrew Searles, Susannah Jefferys, Evan Doran, David A. Henry

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)

Abstract

• Draft legislation introduced to Parliament on 24 May 2007 proposes changes to the Pharmaceutical Benefits Scheme (PBS), including the creation of two formularies. The F1 formulary will contain single brand drugs that are not considered "interchangeable on an individual patient basis", while the F2 formulary will contain mainly older drugs (many of them generic) for which there is at least one alternative product considered to be clinically interchangeable. • Drugs in F1 will not be compared with those in F2 for pricing purposes, even if clinical trial data show them to be equivalent (or even inferior) for the same clinical indication. This undermines the evidence-based approach to reference pricing currently used in the PBS. • Other changes require compulsory price disclosures and price cuts for generic medicines. While positive, these amendments are unlikely to deliver generic medicine prices as low as those in other developed countries. This is important, in view of growing evidence of the unaffordability of prescription medicines in the Australian community.

Original languageEnglish
Pages (from-to)236-239
Number of pages4
JournalMedical Journal of Australia
Volume187
Issue number4
Publication statusPublished - 20 Aug 2007
Externally publishedYes

Fingerprint

Generic Drugs
Formularies
Costs and Cost Analysis
Pharmaceutical Preparations
Disclosure
Legislation
Developed Countries
Prescriptions
Medicine
Clinical Trials

Cite this

Searles, Andrew ; Jefferys, Susannah ; Doran, Evan ; Henry, David A. / Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. In: Medical Journal of Australia. 2007 ; Vol. 187, No. 4. pp. 236-239.
@article{56952b2a30e94e78a3571f92ad54ed84,
title = "Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme",
abstract = "• Draft legislation introduced to Parliament on 24 May 2007 proposes changes to the Pharmaceutical Benefits Scheme (PBS), including the creation of two formularies. The F1 formulary will contain single brand drugs that are not considered {"}interchangeable on an individual patient basis{"}, while the F2 formulary will contain mainly older drugs (many of them generic) for which there is at least one alternative product considered to be clinically interchangeable. • Drugs in F1 will not be compared with those in F2 for pricing purposes, even if clinical trial data show them to be equivalent (or even inferior) for the same clinical indication. This undermines the evidence-based approach to reference pricing currently used in the PBS. • Other changes require compulsory price disclosures and price cuts for generic medicines. While positive, these amendments are unlikely to deliver generic medicine prices as low as those in other developed countries. This is important, in view of growing evidence of the unaffordability of prescription medicines in the Australian community.",
author = "Andrew Searles and Susannah Jefferys and Evan Doran and Henry, {David A.}",
year = "2007",
month = "8",
day = "20",
language = "English",
volume = "187",
pages = "236--239",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AUSTRALASIAN MED PUBL CO LTD",
number = "4",

}

Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. / Searles, Andrew; Jefferys, Susannah; Doran, Evan; Henry, David A.

In: Medical Journal of Australia, Vol. 187, No. 4, 20.08.2007, p. 236-239.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme

AU - Searles, Andrew

AU - Jefferys, Susannah

AU - Doran, Evan

AU - Henry, David A.

PY - 2007/8/20

Y1 - 2007/8/20

N2 - • Draft legislation introduced to Parliament on 24 May 2007 proposes changes to the Pharmaceutical Benefits Scheme (PBS), including the creation of two formularies. The F1 formulary will contain single brand drugs that are not considered "interchangeable on an individual patient basis", while the F2 formulary will contain mainly older drugs (many of them generic) for which there is at least one alternative product considered to be clinically interchangeable. • Drugs in F1 will not be compared with those in F2 for pricing purposes, even if clinical trial data show them to be equivalent (or even inferior) for the same clinical indication. This undermines the evidence-based approach to reference pricing currently used in the PBS. • Other changes require compulsory price disclosures and price cuts for generic medicines. While positive, these amendments are unlikely to deliver generic medicine prices as low as those in other developed countries. This is important, in view of growing evidence of the unaffordability of prescription medicines in the Australian community.

AB - • Draft legislation introduced to Parliament on 24 May 2007 proposes changes to the Pharmaceutical Benefits Scheme (PBS), including the creation of two formularies. The F1 formulary will contain single brand drugs that are not considered "interchangeable on an individual patient basis", while the F2 formulary will contain mainly older drugs (many of them generic) for which there is at least one alternative product considered to be clinically interchangeable. • Drugs in F1 will not be compared with those in F2 for pricing purposes, even if clinical trial data show them to be equivalent (or even inferior) for the same clinical indication. This undermines the evidence-based approach to reference pricing currently used in the PBS. • Other changes require compulsory price disclosures and price cuts for generic medicines. While positive, these amendments are unlikely to deliver generic medicine prices as low as those in other developed countries. This is important, in view of growing evidence of the unaffordability of prescription medicines in the Australian community.

UR - http://www.scopus.com/inward/record.url?scp=34848859630&partnerID=8YFLogxK

M3 - Article

VL - 187

SP - 236

EP - 239

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 4

ER -